A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugate

Duthie, Malcolm S.; Raychaudhuri, Ruben; Tutterrow, Yeung L.; Misquith, Ayesha; Bowman, Julie; Casey, Allen; Balagon, Marivic; Maghanoy, Armi; Beltrán-Alzate, Juan Camilo; Romero-Alzate, Marcela; Cardona-Castro, Nora; Reed, Steven G.

doi:10.1016/j.diagmicrobio.2014.02.006

Cited by 70 publications

(61 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, the gold standard for leprosy diagnosis is based on clinical examination and skin biopsy. Techniques based on PCR technology and serological analysis have been developed but were not able to diagnose leprosy with acceptable sensitivity and specificity taking into consideration the different clinical forms and/or bacterial burden (11,(14)(15)(16)(18)(19)(20)(21). Accordingly, identification of biomarkers that allow the diagnosis of leprosy with a greater sensitivity and specificity is still needed.…”

Section: Discussionmentioning

confidence: 99%

Characterization of MicroRNA Expression Profiles and Identification of Potential Biomarkers in Leprosy

et al. 2017

View full text Add to dashboard Cite

Leprosy is an important cause of disability in the developing world. Early diagnosis is essential to allow for cure and to interrupt transmission of this infection. MicroRNAs (miRNAs) are important factors for host-pathogen interaction and they have been identified as biomarkers for various infectious diseases. The expression profile of 377 microRNAs were analyzed by TaqMan low-density array (TLDA) in skin lesions of tuberculoid and lepromatous leprosy patients as well as skin specimens from healthy controls. In a second step, 16 microRNAs were selected for validation experiments with reverse transcription-quantitative PCR (qRT-PCR) in skin samples from new individuals. Principal-component analysis followed by logistic regression model and receiver operating characteristic (ROC) curve analyses were performed to evaluate the diagnostic potential of selected miRNAs. Four patterns of differential expression were identified in the TLDA experiment, suggesting a diagnostic potential of miRNAs in leprosy. After validation experiments, a combination of four miRNAs (miR-101, miR-196b, miR-27b, and miR-29c) was revealed as able to discriminate between healthy control and leprosy patients with 80% sensitivity and 91% specificity. This set of miRNAs was also able to discriminate between lepromatous and tuberculoid patients with a sensitivity of 83% and 80% specificity. In this work, it was possible to identify a set of miRNAs with good diagnostic potential for leprosy.KEYWORDS biomarker, leprosy, miRNA L eprosy is a chronic infectious disease caused by the bacillus Mycobacterium leprae. The infection affects primarily the skin and can cause damage to peripheral nerves, mucosa, and other organs, including liver and eyes. Leprosy is classified as a neglected tropical disease and remains one of the main causes of disability in the world (1-3). According to a World Health Organization (WHO) report including data from 138 countries, 211,974 newly diagnosed patients were notified in the year 2015 and 96% of them were reported from 22 countries, including Brazil (4).Leprosy presents a spectrum of clinical manifestations depending on the host immune response against M. leprae. It can be classified according to histopathological (Ridley-Jopling) criteria into different forms across two opposing poles: a so-called resistance pole responsible for a localized form of the disease (tuberculoid tuberculoid [TT]) and a susceptibility pole that is a disseminated form, which leads to the development of more severe clinical manifestations (lepromatous leprosy [LL]). There are also three intermediate and unstable forms: borderline tuberculoid (BT), borderline

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of MicroRNA Expression Profiles and Identification of Potential Biomarkers in Leprosy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…One of the antigens of M. leprae, known as phenolic glycolipid-1 (PGL1), was studied for diagnostic test purposes. Several epidemiological studies used a specific serology test to detect anti-PGL1 IgM or a more recently developed test that can detect both anti-PGL1 IgM and anti-LID1 IgG (fusion protein specific to M. leprae) [51]. This serology test is neither marketed nor recommended because of its low sensitivity, especially for paucibacillary presentations of leprosy (thus offering a limited added value), and its inadequate specificity for population of patients frequently infected by other tuberculoid and non-tuberculoid mycobacteria [52].…”

Section: Immunological Diagnosticmentioning

confidence: 99%

Update on the epidemiology, diagnosis, and treatment of leprosy

Reibel

Cambau

Aubry

2015

Médecine et Maladies Infectieuses

121

View full text Add to dashboard Cite

“…The possibility and feasibility of carrying out large-scale screening campaigns to detect antibodies against PGL-I, LID-1, and NDO-LID should therefore be investigated as a means to identify M. leprae-infected individuals (5) . Regular and sustained monitoring of suspected cases is also suggested (29) .…”

Section: Surveillance Of Household Contacts and At-risk Populationsmentioning

confidence: 99%

“…Indeed, laboratory-based ELISA has been used to analyze seroreactivity against PGL-I (4) (5) (17) , LID-1 (4) (5) (17) , ML0405, ML2331 (4) (17) , and NDO-LID (5) (29) . On the other hand, ML Flow is a simple, fast (9) , and reliable tool to detect anti-PGL-I (10) using NTP as antigen, a semi-synthetic trisaccharide analog of PGL-I that is chemically linked to either bovine or human serum albumin (11) .…”

Section: Use Of Serological Assays In Diagnosis Of Leprosymentioning

confidence: 99%

“…Among the most advanced tools in development are tests to detect antibodies against phenolic glycolipid-I (PGL-I), or its di-and trisaccharide analogs NDO and NTP, respectively. Additional diagnostic markers include antibodies against Leprosy IDRI Diagnostic-1 (LID-1), which is a fusion of the ml0405 and ml2331 gene products (4) , as well as antibodies against NDO-LID, a conjugate of natural disaccharide octyl (NDO) and LID (5) . In this study, we mined the available peer-reviewed scientific literature to assess the value of serological tests in leprosy control programs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Integrative literature review of the reported uses of serological tests in leprosy management

Fabri

Carvalho

Vieira

et al. 2016

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugate

Cited by 70 publications

References 23 publications

Characterization of MicroRNA Expression Profiles and Identification of Potential Biomarkers in Leprosy

Characterization of MicroRNA Expression Profiles and Identification of Potential Biomarkers in Leprosy

Update on the epidemiology, diagnosis, and treatment of leprosy

Integrative literature review of the reported uses of serological tests in leprosy management

Contact Info

Product

Resources

About